This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
PCRX vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
PCRX vs. ZTS: Which Stock Is the Better Value Option?
Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues In Line
by Zacks Equity Research
Pacira (PCRX) beats earnings estimates in the fourth quarter of 2019. Revenues are in line with estimates.
Top Ranked Momentum Stocks to Buy for February 21st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 21st
Bausch's (BHC) Q4 Earnings Match Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) reports mixed fourth-quarter results, with earnings meeting expectations but sales missing the same.
3 Top-Ranked Stocks Poised for an Earnings Beat
by Sanghamitra Saha
Count on these top-ranked stocks that are likely to beat earnings estimates in their next releases.
Zoetis' (ZTS) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Zoetis (ZTS) beats on both earnings and sales in the fourth quarter of 2019.
FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA
by Zacks Equity Research
The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.
Will Pacira BioSciences Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Pacira BioSciences.
The Zacks Analyst Blog Highlights: Meritage Homes, Cable One, GoDaddy, Pacira and Great Lakes Dredge
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Meritage Homes, Cable One, GoDaddy, Pacira and Great Lakes Dredge
The Zacks Analyst Blog Highlights: GoDaddy, Great Lakes Dredge, LPL and Pacira BioSciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GoDaddy, Great Lakes Dredge, LPL and Pacira BioSciences
5 Big Winners From Trump's State of the Union Address
by Tirthankar Chakraborty
Trump touted stock market's record run in the State of the Union speech, and painted a rosy picture of the economy. Given the positives, investing in growth stocks won't be a bad proposition.
4 Top Growth Stocks to Buy as Coronavirus Fears Subside
by Tirthankar Chakraborty
The People's Bank of China offered funds in the overnight market to the tune of $71 billion for the second successive day to alleviate the economic stress of containing the viral outbreak.
Pacira BioSciences Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Pacira BioSciences has been struggling lately, but the selling pressure may be coming to an end soon.
Heron Therapeutics (HRTX) Catches Eye: Stock Jumps 6.8%
by Zacks Equity Research
Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
New Strong Buy Stocks for January 21st
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:
ASRT or PCRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ASRT vs. PCRX: Which Stock Is the Better Value Option?
Pacira's (PCRX) Exparel Meets Key Goals in C-Section Study
by Zacks Equity Research
Pacira's (PCRX) phase IV CHOICE study on its lead drug Exparel in patients undergoing Cesarean section attains the primary as well as key secondary endpoints.
Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study
by Zacks Equity Research
Soleno Therapeutics (SLNO) achieves enrollment target in the phase III study evaluating Diazoxide Choline Controlled-Release tablets for treating patients with Prader-Willi Syndrome. Stock up.
ASRT vs. PCRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. PCRX: Which Stock Is the Better Value Option?
Pacira's Late-Stage Study on Exparel Label Expansion Positive
by Zacks Equity Research
Pacira (PCRX) releases positive top-line data from its phase III PLAY study evaluating the pharmacokinetics and safety of Exparel in two patient groups.
Pacira's Exparel Spurs Growth, Exclusive Reliance a Concern
by Zacks Equity Research
Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging. However, sole dependence on the drug is a constant worry.
ASRT vs. PCRX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. PCRX: Which Stock Is the Better Value Option?
Pacira (PCRX) Up 7.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) third-quarter results reflect an earnings beat while revenues almost match estimates. Exparel drives year-over-year growth.
Pacira (PCRX) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of 41.18% and -0.33%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?